Adaptive Biotechnologies Profit Margin

The latest profit margin for ADPT is -20.73% as of June 2026. That compares with -59.07% in the prior-year period — up 64.9% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Adaptive Biotechnologies's historical trend and sector peers before judging valuation or financial health.

Over the past year, ADPT's profit margin moved from -59.07% to -20.73% — a 64.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adaptive Biotechnologies's valuation or profitability profile.

Against Healthcare companies, ADPT currently prints -20.73% for profit margin, while the sector average sits near 21.34%. That is roughly 197.1% below the sector mean. Large gaps often invite a closer look at Adaptive Biotechnologies's growth, margins, and balance sheet.

Profit Margin shows how effectively Adaptive Biotechnologies converts resources into returns. At -20.73%, ADPT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -59.07% in the prior-year period — up 64.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ADPT's profit margin (-20.73%), review year-over-year change from -59.07%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.